Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gilead Sciences, a Bio-pharmaceutical company that manufactures, discovers, develops and commercialises therapies for viral diseases, infectious diseases and cancer, has reported total revenues of $2.08bn for the first quarter ended March 31, 2010, an increase of 36%, compared to $1.53bn for the comparable period in 2009.
Subscribe to our email newsletter
Gilead Sciences posted a net income of $852m for the first quarter 2010, compared to $586.57m for the prior year period. Income from operations was $1.16bn, compared to $808.3m for the year ago period.
Product sales increased 24% to $1.79bn for the first quarter of 2010, compared to $1.45bn in the first quarter of 2009. The increase in sales was driven primarily by Gilead’s antiviral franchise, including the strong growth in sales of Atripla and continued growth in sales of Truvada, as well as the addition of Ranexa to Gilead’s commercial portfolio.